Skip to main content

Table 5 Utility decrements for minor and major bleeding events using regression-based approach (primary analysis) and alternative approach (sensitivity analysis); mean (standard deviation)

From: Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study

Instrument

Primary Analysis

Sensitivity Analysis

Minor Bleeda

Major Bleedb

Minor Bleedc

Major Bleedd

EQ-5D-3 L UK tariff (n = 21)

− 0.00250 (0.00265)

− 0.0297 (0.0478)

− 0.00828 (0.0155)

− 0.0621

(0.103)

EQ-5D-3 L US tariff (n = 21)

− 0.00180 (0.00190)

− 0.0203 (0.0328)

− 0.00584 (0.0102)

− 0.0441 (0.0705)

EQ-5D-5 L to EQ-5D-3 L UK value set (n = 19; n = 20)e

− 0.00140 (0.00280)

−0.0258 (0.0421)

− 0.00661

(0.00911)

−0.0552 (0.0830)

EQ-5D-5 L to EQ-5D-3 L US value set (n = 19; n = 20)e

− 0.00137 (0.00275)

−0.0187 (0.0305)

− 0.00566 (0.00880)

− 0.0405 (0.0597)

EQ-5D-5 L UK tariff (n = 19; n = 20)e

− 0.000848 (0.00170)

− 0.0222 (0.0362)

− 0.00453 (0.00614)

−0.0465 (0.0700)

  1. aUtility decrements obtained by multiplying the regression coefficient for the bleeding event identifier variable by the mean number of days (7.60 days for EQ-5D-3 l and 10.93 for EQ-5D-5 L) that a minor bleed is expected to affect health-related quality-of-life and dividing the product by 365 days
  2. bUtility decrements obtained by multiplying the regression coefficient for the bleeding event identifier variable by the mean number of days (45.38 days for EQ-5D-3 L and 48.75 for EQ-5D-5 L) that a major bleed is expected to affect health-related quality-of-life and dividing the product by 365 days
  3. cUtility decrements obtained by subtracting the health state utility value associated with Vignette A (minor bleed) from one (perfect health) and multiplying by the mean number of days (7.60 days for EQ-5D-3 l and 10.93 for EQ-5D-5 L) that a minor bleed is expected to affect health-related quality-of-life and dividing the product by 365 days
  4. dUtility decrements obtained by subtracting the health state utility value associated with Vignette B (major bleed) from one (perfect health) and multiplying by the mean number of days (45.38 days for EQ-5D-3 L and 48.75 for EQ-5D-5 L) that a major bleed is expected to affect health-related quality-of-life and dividing the product by 365 days
  5. eOne participant did not complete the EQ-5D-5 L for either Vignette A or B and one participant only responded to the pain and anxiety domains for the EQ-5D-5 L for Vignette A resulting in two missing values for minor bleeds and one missing value of major bleeds